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1 Department of Microbiology and Immunology, New York Medical College, Valhalla, NY, United States, 2 College of
Pharmacy, Touro University California, Vallejo, CA, United States, 3 Department of Basic and Clinical Sciences, School of Arts
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Francisella tularensis, the causative agent of the fatal human disease known as tularemia
is classified as a Category A Select Agent by the Centers for Disease Control. No
licensed vaccine is currently available for prevention of tularemia in the United States.
Previously, we published that a tri-antigen tobacco mosaic virus (TMV) vaccine confers
50% protection in immunized mice against respiratory tularemia caused by F. tularensis.
In this study, we refined the TMV-vaccine formulation to improve the level of protection in
immunized C57BL/6 mice against respiratory tularemia. We developed a tetra-antigen
vaccine by conjugating OmpA, DnaK, Tul4, and SucB proteins of Francisella to TMV.
CpG was also included in the vaccine formulation as an adjuvant. Primary intranasal
(i.n.) immunization followed by two booster immunizations with the tetra-antigen TMV
vaccine protected 100% mice against i.n. 10LD100 challenges dose of F. tularensis
live vaccine strain (LVS). Mice receiving three immunization doses of tetra-antigen TMV
vaccine showed only transient body weight loss, cleared the infection rapidly, and
showed minimal histopathological lesions in lungs, liver, and spleen following a lethal
respiratory challenge with F. tularensis LVS. Mice immunized with the tetra-antigen TMV
vaccine also induced strong ex vivo recall responses and were protected against a
lethal challenge as late as 163 days post-primary immunization. Three immunization
with the tetra-antigen TMV vaccine also induced a stronger humoral immune response
predominated by IgG1, IgG2b, and IgG2c antibodies than mice receiving only a single or
two immunizations. Remarkably, a single dose protected 40% of mice, while two doses
protected 80% of mice from lethal pathogen challenge. Immunization of Interferon-
gamma (IFN-γ)-deficient mice with the tetra-antigen TMV vaccine demonstrated an
absolute requirement of IFN-γ for the generation of protective immune response against
a lethal respiratory challenge with F. tularensis LVS. Collectively, this study further
demonstrates the feasibility of TMV as an efficient platform for the delivery of multiple
F. tularensis antigens and that tetra-antigen TMV vaccine formulation provides complete
protection, and induces long-lasting protective and memory immune responses against
respiratory tularemia caused by F. tularensis LVS.
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INTRODUCTION
Francisella tularensis causes the highly lethal disease known as
tularemia in humans especially when the infection is acquired
through the respiratory route. Tularemia remains endemic in
many regions of the world and outbreaks continue to affect
thousands each year (Centers for Disease Control and Prevention
[CDC], 2002; Tarnvik et al., 2004; Eisen et al., 2008; Centers
for Disease Control and Prevention [CDC], 2013; Gurcan,
2014). The pathogenic strains of Francisella belong to subspecies
tularensis (Type A) or subspecies holarctica (Type B). Pneumonic
tularemia causes 30–60% mortality in untreated cases following
inhalation of as few as 10 bacteria (Feldman et al., 2001; Sjostedt,
2007). In addition, F. tularensis is categorized among the most
prominent threats for use as a bioterror agent as it can be
rapidly disseminated by aerosols and can cause widespread
severe illness and death (Bossi and Bricaire, 2003; Cronquist,
2004). As F. tularensis has been used in bioweapon programs
in the past and may potentially be used as a bioterror agent, it
poses a clear and present threat to public health. As a result,
F. tularensis has been classified as Tier 1 Category A Select
Agent by the Centers for Disease Control. Antibiotic resistance,
either through engineering or natural occurrence, undermines
all currently available therapeutic options for treatment of
respiratory tularemia. Currently, no FDA approved vaccine is
available in the United States for prevention of tularemia. Thus,
there is an urgent need for development of safe and effective
vaccines.
Francisella tularensis is an intracellular pathogen; however,
an extracellular phase for F. tularensis has also been reported
(Forestal et al., 2007; Yu et al., 2008). Interferon-gamma (IFN-γ),
tumor-necrosis factor, neutrophils, and other phagocytic cells
play important roles in protection against F. tularensis infection,
although they may be most critical during primary infections
(Sjostedt et al., 1996; Chong and Celli, 2010; Allen, 2013).
Earlier studies reported that cell-mediated but not the humoral
immunity is critical for protection against tularemia, since
vaccination of humans with live attenuated but not killed
organisms resulted in protection against a virulent strain
(Tarnvik, 1989). Nevertheless, protection of mice against
F. tularensis LVS can in fact be passively transferred to naive
animals with immune serum (Kirimanjeswara et al., 2007).
Antibodies alone have not to-date successfully protected mice
against a challenge with a virulent Type A strain; however;
they do slow the course of a Type A infection (Fulop et al.,
2001; Conlan et al., 2002). It has also been reported that
antibodies can provide therapeutic and prophylactic protection
against pulmonary tularemia only in the presence of an active
cell-mediated immune (CMI) response (Kirimanjeswara et al.,
2007, 2008). Both the CD4 or CD8 cells are required for control
of primary F. tularensis infection or vaccine induced protective
Abbreviations: ATCC, American Type Culture Collection; BSL-3, biosafety level
3; CFU, colony forming units; CMI, cell-mediated immunity; EDC, 1-ethyl-
3-(3-dimethylaminopropyl) carbodiimide hydrochloride; FDA, Food and Drug
Administration; i.n., intranasal; LD, lethal dose; LPS, lipopolysaccharide; LVS, live
vaccine strain; MH, Mueller–Hinton; NHS, 5 mM N-hydroxysulfosuccinimide;
TMV, tobacco mosaic virus.
immunity (Wu et al., 2005; Bakshi et al., 2008). These studies
demonstrated that generation of both humoral and cellular
immunity is required for protection against tularemia.
Majority of tularemia vaccine studies are in pre-clinical stages
and no lead vaccine candidate has been identified to-date for
evaluation in humans. Multiple approaches for the development
of tularemia vaccine have been attempted with little success.
Immunization with a killed vaccine caused local reactions,
induced poor CMI responses, and failed to provide protection
against respiratory F. tularensis SchuS4 challenge (Burke, 1977;
Baron et al., 2007). The live-attenuated strains including the
LVS has succeeded in providing protection against a low dose of
F. tularensis Schus4 challenge in mice and non-human primates,
but they do not offer a high degree of protection against high
dose aerosol challenge with F. tularensis SchuS4 (Belyi et al., 1995;
Oyston and Quarry, 2005; Bakshi et al., 2008; Barry et al., 2009;
Mahawar et al., 2013; Marohn and Barry, 2013; Chu et al., 2014).
Moreover, reversion to fully virulent form is always a possibility
with live-attenuated vaccines. Studies involving subunit vaccine
development against tularemia have identified a number of
F. tularensis antigens which have the capability of inducing a
protective immune response (Holm et al., 1980; Eyles et al., 2007).
On the other hand, single antigenic components of F. tularensis
such as GroEL, DnaK, FopA, KatG, LPS O antigens, or Tul4
are safe when used as vaccines, but elicit a limited protective
immune response against respiratory tularemia (Conlan et al.,
2002; Apicella et al., 2010; Hickey et al., 2011; Kaur et al., 2012).
Complex subunit vaccine formulations consisting of more than
one purified antigenic component or a mixture of antigens either
in the form of outer membrane proteins or F. tularensis LVS
and SchuS4 lysates have shown improved protection against
respiratory challenge with F. tularensis (Huntley et al., 2008;
Ashtekar et al., 2012; Richard et al., 2014, 2017). However,
non-availability of a suitable platform for delivering protective
antigens simultaneously through a mucosal route has been the
biggest hurdle in development of tularemia subunit vaccine.
In our previous study, we employed a novel approach for
the development of a multi-antigen subunit vaccine against
tularemia by using TMV-based delivery platform. We have
shown that tri-antigen TMV vaccine consisting of OmpA,
DnaK, and Tul4 proteins of F. tularensis SchuS4 generated
a TH2 predominated humoral immune response indicated
by higher levels of F. tularensis-specific IgG1 antibodies and
provided only 50% protection in immunized C57BL/6 mice
(Banik et al., 2015). In the present study, we refined the
TMV-vaccine formulation to improve the level of protection
in immunized C57BL/6 mice against respiratory tularemia.
We improved the tri-antigen TMV vaccine (OmpA, DnaK,
and Tul4) by including dihydrolipoamide succinyl transferase
(SucB) protein of F. tularensis SchuS4 into a tetra-antigen
formulation. A CpG adjuvant was also incorporated into the
vaccine formulation to induce a TH1 biased humoral immune
response. The results from this study demonstrate that tetra-
antigen TMV vaccine formulation with CpG adjuvant provides
100% protection in immunized C57BL/6 mice and induces a
long-term protection against respiratory tularemia caused by
F. tularensis LVS.
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MATERIALS AND METHODS
Bacterial Strains
Francisella tularensis LVS (American Type Culture, ATCC 29684;
Rockville, MD, United States) and F. tularensis SchuS4 strains
used in this study were obtained from BEI Resources, Manassas,
VA, United States. All F. tularensis LVS strains were handled
in a Bio Safety Level-2 (BSL-2) laboratory. The F. tularensis
SchuS4 strain was handled in a CDC approved BSL-3 facility
at New York Medical College. F. tularensis LVS and SchuS4
were cultured on MH chocolate agar plates (BD Biosciences,
San Jose, CA, United States) and grown for 48 h at 37◦C in
an atmosphere of 5% CO2. Briefly, grown single colonies were
picked and resuspended in MH-broth (MHB; BD Biosciences,
San Jose, CA, United States) supplemented with 0.021% w/v
anhydrous calcium chloride; 0.000138% w/v hydrous magnesium
chloride; 0.00021% w/v 10% glucose, 10% v/v; 2.5% ferric
pyrophosphate, and 2.5% v/v Isovitalex (BD Biosciences, San
Jose, CA, United States). The suspension was incubated at 37◦C
with shaking at 160 rpm until an OD600 of 0.2 was achieved.
The active mid-log phase bacteria were aliquoted into sterile
1.5 ml cryovials and stored at −80◦C for further use. For
challenge experiments, the frozen cultures of F. tularensis LVS
were streaked on MH-chocolate agar plates and incubated at
37◦C in the presence of 5% CO2 for 36 h. A bacterial suspension
was made in sterile PBS by adjusting OD600 to 0.2, which
corresponds to 1 × 109 CFU/ml. The bacteria were diluted to
achieve a final concentration of 1× 105 CFU/20 µl and were used
in all challenge experiments.
Mice
All mice experiments were performed according to the
guidelines and protocols approved by the IACUC at New York
Medical College. For vaccination and challenge studies,
wild-type C57BL/6 mice were purchased from Charles River
Laboratories. The C57BL/6 IFN-γ knockout (B6.IFN-γ−/−)
(Dalton et al., 1993) and their corresponding wild-type C57BL/6J
(B6.IFN-γ+/+) mice were purchased from The Jackson
Laboratories. Six-to-eight week old mice of either sex were
used in all the vaccination and challenge studies. All mice were
maintained in an environmentally controlled and pathogen-free
animal facility of the New York Medical College.
Tobacco Mosaic Virus (TMV)
Tobacco mosaic virus was engineered to express coat protein
containing a surface exposed lysine (Smith et al., 2007).
Infectious TMV RNA was inoculated onto a 30-day-oldNicotiana
benthamiana plant, and harvested for virus 10 days later
according to previously described protocols (Smith et al., 2006).
Briefly, the plant tissue was homogenized in 0.86 M sodium
chloride, 0.04% w/v sodium metabisulfite (0.5 g of tissue/ml of
buffer), adjusted to a pH of 5.0, heated to 47◦C for 5 min, and
then chilled to 4◦C. Homogenate was centrifuged at 6000 × g
for 20 min, and then the clarified supernatant was precipitated
with 5% poly ethylene glycol (PEG) 8000 at 4◦C, and spun
at 12,000 × g for 10 min at 4◦C to recover the virus. PEG
pellets were re-suspended in PBS, and re-precipitated with
PEG a second time. The final PEG pellets were re-suspended
in PBS at 1:10 homogenization volume, and final protein
concentration was measured using bicinchoninic acid (BCA)
kit.
Adjuvant
A synthetic endotoxin-free oligodeoxynucleotide comprising of
unmethylated CpG motifs (CpG 1826, Invivogen) was blended in
the vaccine formulation and 20 µg of CpG was administered with
each immunization.
Expression, Purification, and
Conjugation of Recombinant Proteins
The selection and prioritization of F. tularensis protein antigens
used in the TMV-vaccine formulation was based on the
immunoproteomic analysis from previously published studies.
Antibodies against OmpA (FTT0831c), DnaK (FTT1269c), Tul4
(FTT0901), and dihydrolipoamide succinyl transferase (SucB)
(FTT0077) proteins of F. tularensis SchuS4 have been identified
exclusively in serum isolated from human patients with a prior
history of infection with F. tularensis Type A strains, or those
vaccinated with F. tularensis LVS (Havlasova et al., 2002, 2005;
Eyles et al., 2007; Janovska et al., 2007). This was the basis
for inclusion of these proteins in our vaccine formulation.
For expression of these proteins, genes of F. tularensis SchuS4
encoding for OmpA (FTT0831c), DnaK (FTT1269c), Tul4
(FTT0901), and SucB (FTT0077) were cloned in Escherichia
coli expression vectors, expressed, and purified following our
previously published protocols (Banik et al., 2015). The purity
of the recombinant proteins was confirmed by SDS-PAGE
and western blot analysis using anti-6His antibodies. Each of
the recombinant F. tularensis SchuS4 protein was chemically
conjugated to the surface of TMV. TMV-DnaK, TMV-OmpA,
TMV-SucB, and TMV-Tul4 conjugates were generated as
described previously with slight modifications (Mallajosyula
et al., 2014; Banik et al., 2015; Arnaboldi et al., 2016). The purified
TMV 1295.10 expressing a surface lysine (Smith et al., 2006)
was mixed at a 1:1 mass ratio for DnaK, OmpA, and SucB to
avoid steric hindrance due to the higher molecular weights of
these proteins (70, 55, and 60 kD, respectively). For conjugation
of Tul4, which has a very low molecular weight of 14.5 kD, the
TMV and Tul4 were mixed in a 1:1 molar ratio. The conjugation
reaction was carried out by adding 100 mM 2-(N-morpholino)
ethanesulfonic acid and 500 mM NaCl solution at pH 6.0.
Subsequently, EDC hydrochloride followed by NHS were added
to the reaction mixture. EDC concentrations and the duration
of the reactions were optimized to observe that no “free”
protein antigen was left after the reaction, which varied for
each individual protein. The conjugation reactions were stopped
with 1 mM methylamine, and then conjugates were dialyzed
against PBS overnight (Slidalyzer, 10 kD MCO). Following
dialysis, the concentration of each TMV–protein conjugate
was determined using BCA assay (BCA BioRad). SDS-PAGE
using 8–16% gel (BioRad) followed by Coomassie blue staining
was performed to visualize TMV–protein conjugates. The
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TMV–protein conjugates were stored at −20◦C until used for
immunizations.
Vaccine Formulation
All the four (DnaK, OmpA, Tul4, and SucB) recombinant
protein–TMV conjugates (consisting of 10 µg TMV + 10 µg of
each recombinant protein) were mixed at an equal concentration
to yield a tetra-antigen TMV vaccine. A group of 10–12 mice each
were immunized with tetra-antigen TMV vaccine. Each mouse
was inoculated i.n. with 80 µg of tetra-antigen–TMV vaccine,
which contained 40 µg of four recombinant F. tularensis proteins
(10 µg each) and 40 µg TMV with 20 µg of CpG adjuvant (CpG
1826, Invivogen) in 40 µl PBS (20 µl/nare). Control mice received
40 µg TMV (unconjugated) with 20 µg of CpG adjuvant in 40 µl
PBS i.n. (20 µl/nare).
Immunization Schedule
C57BL/6 mice were deeply anesthetized by intraperitoneal (i.p.)
injection of a cocktail of ketamine and xylazine to overcome
the regurgitation reflexes and to facilitate delivery of the vaccine
into the lungs. Groups of mice (n = 7–12) were immunized by
i.n. route with 40 µl (20 µl/ nostril) volume of tetra-antigen
TMV vaccine along with CpG adjuvant in PBS. All mice
immunized with tetra-antigen TMV vaccine either did not
receive any booster immunization, received an additional booster
immunization with a similar dose on day 14, or received
two booster immunizations on days 14 and 28 post-primary
immunization. The control mice received TMV + CpG in a
volume of 40 µl during primary as well as booster immunizations.
Challenge Studies
All immunized mice were challenged with 1 × 105 CFU
(10LD100) of F. tularensis LVS i.n. on day 49 post-primary
immunization. In another experiment, mice were challenged
with 10LD100 of F. tularensis LVS on day 163 post-primary
immunization. All mice were deeply anesthetized prior to
challenge as described earlier. All mice were weighed daily
after the challenge to monitor morbidity and the progression
of infection. Mice losing more than 25% body weight were
observed closely and if they became immobile were considered
moribund and euthanized. Mice were observed for survival
for a period of 21 days. All surviving mice were euthanized
at the end of the experiment on day 35 post-challenge. The
undiluted homogenates of lung, liver, and spleens from these
mice were plated on MH chocolate plates. This was done to
determine the presence of any residual infection and to establish
if immunization with tetra-antigen TMV-vaccine provides a
sterilizing immunity as plating whole organ homogenates would
detect even a single bacterium in organs of the challenged mice.
To determine the kinetics of bacterial clearance following
challenge, the control and immunized mice were challenged with
10LD100 of F. tularensis LVS and groups of mice (n = 3–4) were
sacrificed on days 7, 14, and 21 post-challenge. The lungs, livers,
and spleens were collected aseptically and homogenized in a bead
beater using sterile zirconia beads. The organ homogenates were
diluted 10-fold in sterile PBS and plated on MH-Chocolate agar
plates to enumerate the bacterial numbers. The limit of detection
of bacteria by this assay is 1 × 102 CFU/ml. The plates were
incubated for 48 h in the presence of 5% CO2 and colonies were
counted. Small portions of lungs, livers, and spleens were fixed in
10% formalin, embedded in paraffin, and sectioned and stained
with Hematoxylin and Eosin (H&E) stain. The sections were
observed and images were taken on a Nikon Eclipse microscope
using VIS-Elements AR Version 5.02 software at 10× (Numerical
Aperture: 10× 0.30) and 40× (Numerical Aperture: 40× 0.60)
magnifications. Number of granulomas were quantitated in
uninfected and unvaccinated controls and vaccinated mice on
day 7 post-challenge by counting the number of granulomas in 10
random fields under 10× magnification. Liver sections prepared
from three mice per group were used for counting granulomas by
two independent investigators in a blinded fashion. The data were
analyzed by unpaired t-test and the P-values were determined.
Antibody Measurements
For determination of antibody levels in immunized mice
following immunization and challenge, blood was drawn by
retro-orbital venipuncture of anesthetized mice on days 28,
49, 84, or 163 post-primary immunizations, or on day 49
post-challenge and the serum was collected. Control mice were
also bled in a similar fashion. All sera samples were stored at
−20◦C until evaluated for antibody levels. ELISA was performed
using lysates made from F. tularensis LVS or with OmpA, DnaK,
Tul4, or SucB recombinant proteins as previously described
(Banik et al., 2015). Briefly, 96-well microtiter plates were coated
with 7 × 107 CFU/ml of F. tularensis LVS in bicarbonate buffer.
F. tularensis-specific IgG, IgG1, IgG2b, and IgG2c antibody levels
were determined in serum collected from immunized mice on
days 28, 49, 84, and 163 post-primary immunization or on day
49 post-challenge. In order to determine the level of antibodies
induced against each individual protein of the tetra-antigen TMV
vaccine, ELISA plates were coated with purified recombinant
OmpA (10 µg/ml), DnaK, Tul4, or SucB (1 µg/ml) proteins.
Total IgG antibodies (Invitrogen) were used at 1:10,000 dilutions;
while IgG1 (Life Technologies), IgG2b (BioLegend), and IgG2c
(Abcam) isotype-specific antibodies were used at 1:1000, 1:500,
and 1:500 dilutions, respectively. The antigen-specific total IgG
levels were determined in pooled serum from vaccinated mice
collected on days 28 and 49 post-primary immunization, or
on day 49 post-challenge. All antibody end-point titers were
calculated as the inverse of the serum dilution that showed an
OD450 value 2.5 times above the controls, and expressed as Log10
values (Banik et al., 2015).
Ex Vivo Assays
Splenocytes were harvested on day 84 post-primary
immunization from a separate group of mice receiving three
immunizations with tetra-antigen TMV vaccine or from
age-matched control mice. Bone marrow-derived macrophages
(BMDMs) derived from C57BL/6 mice were seeded in a 24-well
plate and incubated for 24 h at 37◦C in 5% CO2. BMDMs were
infected either with F. tularensis LVS or F. tularensis SchuS4 at a
multiplicity of infection (MOI) of 100, incubated for 2 h at 37◦C
in 5% CO2, and treated with gentamicin (250 µg/ml) for 2 h to
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kill all extracellular and adherent bacteria. The infected BMDMs
were overlaid with splenocytes isolated from immunized or
control mice (n = 3) at a ratio of 1:1. The co-cultures were
allowed to progress for 120 h. The cell culture supernatants were
collected at 24, 48, and 120 h and the levels of IL-17 and IFN-γ
were determined by Cytometric Bead Array (CBA). The limits of
detection for IL-17 and IFN-γ by CBA are 18.9 and 3.7 pg/ml,
respectively.
Statistical Analysis
All results were statistically analyzed using Graphpad Prism
Software 6.0 and expressed as mean± SD. Statistical comparisons
were made using one-way ANOVA, unpaired or paired t-test.
The survivals data were expressed as Kaplan–Meier survival
curves and statistical significance was determined by log-rank
test. P < 0.05 was considered as statistically significant.
RESULTS
Tetra-Antigen TMV Vaccine Formulation
The design of tetra-antigen TMV vaccine formulation is shown in
Figure 1A. It has been reported earlier that not all coat proteins
of TMV interact directly with the subunit proteins, and this
interaction is largely governed by steric hindrances caused by
the molecular weight of the interacting protein (Mallajosyula
et al., 2014). Therefore, not every individual coat protein of the
TMV will interact with subunit proteins larger than its molecular
weight of 17 kD. As shown in Figure 1A, the larger the subunit
protein, the fewer molecules of the subunit protein will associate
with the TMV due to steric hindrance at the virus surface.
A successful conjugation of recombinant DnaK, OmpA, SucB,
and Tul4 to TMV was observed by the disappearance of free
protein and/or formation of high molecular weight complexes.
The optimal conjugation conditions for TMV-DnaK were 3 mM
EDC for 3 h; 6 mM EDC for 3 h for TMV-OmpA; 3 mM EDC
for 2 h for TMV-SucB; and 4 mM EDC for 2 h for TMV-Tul4.
The reproducibility of the conjugation reaction was confirmed by
running replicate samples once the conjugation reactions were
optimized (Figure 1B).
Immunization With Tetra-Antigen TMV
Vaccine Provides 100% Protection
Against a Lethal F. tularensis LVS
Challenge
In our previous study, we have demonstrated that immunization
with a tri-antigen vaccine consisting of DnaK, OmpA, and Tul4
protected 50% of C57BL/6 mice against an i.n. 10LD100 challenge
dose of F. tularensis LVS. However, to achieve this degree of
protection, five immunizations by i.n. and subcutaneous routes
were needed (Banik et al., 2015). In this study, we reformulated
the tri-antigen TMV vaccine to include an additional antigen
SucB, to generate a tetra-antigen TMV vaccine. We also included
a CpG adjuvant to our tetra-antigen TMV vaccine to boost a TH1
biased immune response (Figure 1A). Additionally, the number
of immunizations than those used for the tri-antigen vaccine were
FIGURE 1 | Design and formulation of the tetra-antigen TMV vaccine. (A) To
the tri-antigen TMV vaccine consisting of OmpA, DnaK, and Tul4, a fourth
protein antigen, dihydrolipoamide succinyl transferase (SucB), was added to
prepare a tetra-antigen TMV vaccine. Each recombinant protein antigen was
conjugated to TMV separately and then mixed in equal concentrations to
generate the tetra-antigen vaccine. The CpG 1826 adjuvant was also included
in the vaccine formulation. (B) Conjugation of F. tularensis SchuS4
recombinant proteins to TMV. Recombinant proteins purified by Nickel affinity
chromatography were conjugated to TMV as described in the section
“Materials and Methods.” The protein–TMV conjugation was visualized by the
disappearance of free antigen protein and the appearance of higher molecular
weight complexes. M, protein molecular weight marker; 1, TMV; 2,
recombinant protein; 3, protein+TMV mixture; 4–7, protein–TMV conjugate
replicates from several conjugation reactions.
also reduced. Mice received a primary immunization on day 0
and two booster immunizations on days 14 and 28 post-primary
immunization. The immunized mice were challenged i.n. on day
49 post-primary immunization with 10LD100 dose of F. tularensis
LVS (Figure 2A). One hundred percent of the vaccinated mice
survived the challenge, while 100% of unvaccinated control
mice died or were removed from the study due to their
moribund state by day 9 post-challenge. The vaccinated mice
showed an initial reduction in their body weight for the first
3 days, which remained stable for next 8–9 days post-challenge
before starting to regain their pre-challenge body weights. The
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FIGURE 2 | Immunization with tetra-antigen TMV vaccine provides 100% protection and the immunized mice clear infection rapidly following a lethal F. tularensis
LVS challenge. (A) C57BL/6 mice were immunized i.n. on days 0, 14, and 28 with tetra-antigen TMV vaccine formulation as described in the section “Materials and
Methods” and challenged i.n. with 1 × 105 CFU (10LD100) of F. tularensis LVS on day 49 post-primary immunization. (B) Mice were observed for mortality and
morbidity by monitoring survival and body weights. The survival results are expressed as Kaplan–Meier survival curves and the statistical analysis was performed by
log-rank test. The body weight data are represented as mean ± SD (n = 10–12 mice/group). The results are representative of two independent experiments
conducted. (C) Kinetics of bacterial clearance in mice immunized and challenged as shown. The organs were harvested on days 7, 14, and 21 post-challenge and
the bacterial burden in the lung, liver, and spleen of vaccinated and control mice was determined. The results represent the means ± standard errors of CFU counts
(n = 3–4 mice/group/time point) and are from a single experiment conducted. The data were analyzed by one-way ANOVA followed by Bonferroni’s correction and
P-values were determined. The dotted line represents the limit of detection. 9, all control mice succumbed to infection by day 14 post-challenge and hence were not
available for comparisons; ND, not detected.
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unvaccinated control mice, however, experienced severe weight
loss and either did not survive or were euthanized (Figure 2B).
These results demonstrate that the tetra-antigen TMV vaccine
is fully protective against a lethal respiratory challenge with
F. tularensis LVS.
We next investigated the kinetics of bacterial clearance
in vaccinated mice following challenge. Mice received three
immunizations as described above and were challenged on day
49 post-primary immunization. Mice were euthanized on days 7,
14, and 21 post-challenge and bacterial burden was quantitated
in their lungs, livers, and spleens. In the lungs of the immunized
mice, the bacterial numbers were similar to those observed for
the unvaccinated controls on day 7 post-challenge. However,
bacterial numbers declined on days 14 and 21 (Figure 2C).
Bacteria were cleared completely from the lungs of vaccinated
mice by day 35 post-challenge as observed by plating the whole
organ homogenate on MH-chocolate agar plates that would
detect the presence of even a single bacterium in lungs of the
challenged mice. These results indicated that the tetra-antigen
TMV-vaccine provides a sterilizing immunity (not shown). In
livers of the vaccinated mice, the bacterial numbers were not
different from that observed for unvaccinated controls on day
7 post-challenge. The spleens of vaccinated mice harbored
significantly less number of bacteria than the unvaccinated
controls on day 7 post-challenge. Bacterial numbers in livers
and spleens declined on day 14 (similar to lung clearance) and
were completely cleared from livers and spleen of the immunized
mice by day 21 post-challenge. The unvaccinated control mice
either succumbed to infection or were moribund and euthanized;
hence, were not available for comparisons on days 14 and 21
(Figure 2C). These results indicate that immunization with the
tetra-antigen TMV vaccine confers a protective immune response
capable of providing fully sterilizing immunity.
Immunization With Tetra-Antigen TMV
Vaccine Results in Minimal Pathology in
Lung, Liver, and Spleen Following a
Lethal Challenge With F. tularensis LVS
Since mice vaccinated with tetra-antigen TMV vaccine cleared
bacteria from lung, liver, and spleen following F. tularensis LVS
challenge, it was of interest to examine if bacterial clearance
was associated with reduction in the histopathological lesions
in these organs as an additional measure of the vaccine’s
protective efficacy. Portions of lung, liver, and spleen from mice
sacrificed on days 7, 14, and 21 post-challenge (Figure 3A) were
fixed in 10% formalin, embedded in paraffin, and sectioned.
The H&E-stained sections were evaluated for histopathological
lesions.
The unvaccinated control mice showed severe tissue damage
and extensive necrotic lesions in lung, liver, and spleen on
day 7 post-challenge. The lungs of immunized mice revealed
fewer and smaller inflammatory foci on day 7 post-challenge
compared to those observed in lungs of control unvaccinated
mice. The number of inflammatory foci decreased and started
to resolve by day 14. The normal lung architecture with the
exception of few small inflammatory foci was restored by day
21 post-challenge (Figure 3B). Livers of the vaccinated mice
showed significantly lower number of granulomas compared to
those observed in the unvaccinated mice on day 7 post-challenge
(Figures 4A,B). The granulomas gradually reduced in size by
day 14 post-challenge and were no longer observed by day 21
post-challenge in the livers of vaccinated mice (Figure 4A).
Spleens of unvaccinated mice revealed complete disruption of
the splenic architecture, with necrotic splenitis observed on
day 7 post-challenge. Similar to lung and liver on day 7
post-challenge, spleen lesions in the vaccinated mice were far
less severe and showed only mild disruption of the splenic
architecture with greater numbers of infiltrating cells. These
lesions started to resolve by day 14 and the normal splenic
architecture was restored by day 21 post-challenge (Figure 4C).
Since all the unvaccinated mice died before day 14, they
were not available for comparisons. Collectively, these results
demonstrate that mice immunized with tetra-antigen TMV
vaccine clear F. tularensis infection very efficiently without
causing extensive pathological lesions in the lung, liver, or spleen.
Furthermore, vaccinated mice showed complete resolution of
inflammatory lesions in the lung, liver, and spleen by day 21
post-challenge.
Tetra-Antigen TMV Vaccine Induces a
Potent Humoral Immune Response in
Immunized Mice
We determined the contribution of each of the antigen in our
vaccine formulation to the generation of antibody responses.
Pooled serum samples (n = 3 mice) from immunized mice
collected on days 28 and 49 post-primary immunization
as well as on day 49 post-challenge were used for the
determination of total IgG levels against each individual protein
(Figure 5A). The strongest antibody responses were generated
against DnaK followed by Tul4, SucB, and OmpA proteins.
An amplification of antibody responses against these proteins
was observed on day 49, i.e., after receiving the second booster
immunization on day 28 post-primary immunization. These
responses were further enhanced when antibody levels were
determined on day 49 post-challenge, with DnaK being the
most immunogenic followed by Tul4, SucB, and OmpA protein
antigens (Figure 5B).
We also investigated the humoral immune response
in immunized mice receiving none, one, or two booster
immunizations with tetra-antigen TMV vaccine. The levels
of total IgG, IgG1, IgG2b, and IgG2c were determined
using F. tularensis LVS lysates. Mice receiving single
immunization showed antibody responses predominated by
F. tularensis-specific IgG1 antibodies. The total IgG as well as the
levels of all other antibody isotypes were significantly higher in
mice receiving a booster immunization on day 28 post-primary
immunization. The antibody levels in mice receiving two booster
immunization on days 14 and 28 post-primary immunization
were significantly lower than those observed for mice receiving a
single booster immunization. As observed for humoral responses
against each individual protein in mice immunized with two
booster immunizations, the overall total IgG, IgG1, and IgG2c
Frontiers in Microbiology | www.frontiersin.org 7 June 2018 | Volume 9 | Article 1195
fmicb-09-01195 June 1, 2018 Time: 13:26 # 8
Mansour et al. TMV-Based Tularemia Subunit Vaccine
FIGURE 3 | Immunization with tetra-antigen TMV vaccine results in minimal pathology in lung following a lethal challenge with F. tularensis LVS. (A) C57BL/6 mice
were immunized and challenged as shown. Lungs were collected from unvaccinated controls as well as vaccinated mice on days 7, 14, and 21 post-challenge.
Hematoxylin and eosin stained sections of lung (B) were evaluated for histopathological lesions at the indicated times post-challenge. The experiments were
conducted with 3–4 mice/group/time point and the representative images are shown. The sections were observed and images were taken on a Nikon Eclipse
microscope using VIS-Elements AR Version 5.02 software. Small green boxes represent the area shown at 40× magnification in insets (magnification 10×; insets
40×; bar in 10× = 200 µM; bar in 40× = 50 µM). 9, all unvaccinated mice succumbed to infection by day 14 post-challenge and hence were not available for
comparisons.
responses were significantly elevated when monitored on day
49 post-challenge compared to those observed on day 49
post-primary immunization (Table 1). Collectively, these results
demonstrate that the tetra-antigen TMV vaccine is capable
of inducing strong antibody-mediated immune responses in
immunized mice.
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FIGURE 4 | Immunization with tetra-antigen TMV vaccine results in minimal pathology in liver and spleen following a lethal challenge with F. tularensis LVS. C57BL/6
mice were immunized and challenged as shown in Figure 3A. Liver and spleens were collected from unvaccinated controls as well as vaccinated mice on days 7,
14, and 21 post-challenge. Hematoxylin and eosin-stained sections of liver (A) were evaluated for histopathological lesions at the indicated times post-challenge.
The arrows and arrow heads indicate granulomas in livers of unvaccinated controls and mice immunized with tetra-antigen TMV vaccine. (B) Number of granulomas
were quantitated in uninfected and unvaccinated controls on day 7 post-challenge by counting the number of granulomas in 10 random fields under 10×
magnification by two independent investigators in a blinded fashion (n = 3 mice/group). The data were analyzed by unpaired t-test and the P-values were
determined. (C) Hematoxylin and eosin stained sections of spleens were evaluated for histopathological lesions at the indicated times post-challenge. The
experiments were conducted with 3–4 mice/group/time point and the representative images are shown. The sections were observed and images were taken on a
Nikon Eclipse microscope using VIS-Elements AR Version 5.02 software (magnification 10×; bar = 200 µM). 9, all unvaccinated mice succumbed to infection by
day 14 post-challenge and hence were not available for comparisons.
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FIGURE 5 | Total IgG antibody responses in immunized mice pre- and post-challenge against each individual protein of tetra-antigen TMV vaccine. (A) C57BL/6
mice were vaccinated with tetra-antigen TMV vaccine, TMV alone, or left unvaccinated. Mice were challenged on day 49 post-primary immunization.
(B) Antigen-specific total IgG antibody titers were determined at the indicated times in pooled serum samples from immunized mice (n = 3 mice/group) by ELISA.
Each pooled sample was run in duplicate. The results are expressed as absorbance at 450 nm (mean ± standard deviation). The cut-off absorbance values used to
determine the end-point titers are indicated by dashed lines and the actual values are shown in the box (top panels). The end-point titers are represented as Log10
values (bottom panel).
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TABLE 1 | Antibody responses in mice immunized with tetra-antigen TMV vaccine receiving none, one, or two booster immunizations.
Number of boosters Total IgG# P-values∗ IgG1 P-values IgG2b P-values IgG2c P Values
0@ 4.03 ± 0.35 }
P < 0.0001
3.81 ± 0.65 }
P = 0.0005
3.05 ± 0.22 }
P < 0.0001
3.25 ± 0.22 }
P < 0.0001
1@,∞ 6.19 ± 0.24 }
P = 0.0064
6.19 ± 0.24 }
P = 0.011
4.98 ± 0.19 }
P = 0.033
5.64 ± 0.19 }
P = 0.0475
2@ 5.55 ± 0.40 }
P = 0.0015
4.05 ± 0.52 }
P = 0.0360
4.66 ± 0.17 }
ns
5.15 ± 0.40 }
P = 0.0186
2ˆ 6.89 ± 0.63 5.00 ± 0.00 5.00 ± 0.36 5.10 ± 0.0
#Log10 titers expressed as mean ± SD (n = 3–4 mice/group). @Antibody levels determined on day 49 post-primary immunization. ∞These values are same as shown in
Table 3 and are included in Table 1 only for comparisons with other immunization regimens. ˆDay 49 post-challenge. ∗P-values were determined by paired t-test. ns = not
significant.
Tetra-Antigen TMV Vaccine Induces
Potent Recall Response in Immunized
Mice
We determined the duration of protective immune responses
induced in mice receiving two booster immunizations with
tetra-antigen TMV vaccine by performing ex vivo recall
response assays. Mice receiving two booster immunizations
of tetra-antigen TMV vaccine (Figure 6A) were sacrificed
on day 84 post-primary immunization and single-cell spleen
suspensions were prepared. BMDMs isolated from syngeneic
C57BL/6 mice were infected either with F. tularensis LVS or
F. tularensis SchuS4 at an MOI of 100 (100:1 bacteria cell
ratio), for 2 h followed by gentamicin treatment for 2 h. The
infected BMDMs were then overlaid with splenocytes isolated
from immunized mice at 1:1 ratio. Splenocytes isolated from
naïve mice were used as controls. The culture supernatants from
co-culture were analyzed for IFN-γ and IL-17 levels 24, 48, and
120 h later. It was observed that splenocytes from immunized
mice co-cultured with BMDMs infected with F. tularensis LVS
resulted in significantly higher levels of IFN-γ and IL-17 in
culture supernatants collected after 48 and 120 h of co-culture
compared to the naïve controls (Figure 6B). Similar results
were obtained when BMDMs were infected with F. tularensis
SchuS4 and co-cultured with splenocytes from immunized mice
(Figure 6C). Collectively, these results demonstrate that the
tetra-antigen TMV vaccine is capable of inducing long-lasting
recall responses.
Tetra-Antigen TMV Vaccine Induces
Long-Lasting Immunity Against Lethal
F. tularensis LVS Challenge
We next determined the duration of immunity in mice
immunized with tetra-antigen TMV vaccine followed by
two booster immunizations on days 14 and 28 post-primary
immunization. The immunized mice were bled on day 84
post-immunization to determine the antibody levels. The
immunized mice were boosted again on day 91 post-primary
immunization using half of the vaccination dose that
they received during primary and booster immunizations
(Figure 7A). The mice were bled, challenged with 10LD100 dose
of F. tularensis LVS i.n. on day 163 post-primary immunization,
and observed for morbidity and mortality. It was observed that
80% of immunized mice survived the challenge, and after an
initial weight loss, regained their pre-challenge body weights
(Figure 7B). The antibody levels in these immunized mice on
day 84 post-primary immunization were lower across the board
(Table 2) compared to those observed on day 49 post-primary
immunization (Table 1). However, these responses, especially
for total IgG, IgG1, and IgG2c were significantly higher on
day 163 compared to those observed on day 84 (Table 2)
indicating that the enhanced antibody levels are in response
to the additional half dose booster that these mice received on
day 91 post-primary immunization. Collectively, these results
demonstrate that immunization with tetra-antigen TMV vaccine
induces potent memory as well a long-lasting protective immune
response in vaccinated mice.
Protective Efficacy of Tetra-Antigen TMV
Vaccine After One and Two
Immunizations and Dependence on
IFN-γ for the Protection Induced by the
Tetra-Antigen TMV Vaccine
Our preceding results demonstrated that a primary
immunization followed by two booster immunizations on
days 14 and 28 protected 100% mice against a lethal i.n.
challenge with F. tularensis LVS. We next investigated if the same
protective efficacy can be retained by reducing the number of
booster immunizations. C57BL/6 mice either received only one
immunization (day 0) or an additional booster immunization on
day 28 (Figures 8A, 9A) using similar doses of tetra-adjuvant
TMV vaccine as described above. The immunized mice were
challenged with 1 × 105 CFU of F. tularensis LVS i.n. on day
49 post-primary immunization. As observed earlier, all the
unvaccinated control mice succumbed to infection by day 13
post-challenge. Remarkably, 40% of the vaccinated mice that
received a single vaccine dose (day 0) survived the challenge.
A drastic weight loss was observed in unvaccinated control mice;
while in the vaccinated group, all the surviving mice regained
their pre-challenge body weights after an initial loss (Figure 8B).
Survival from lethal i.n. challenge was improved to ∼80% after
mice received one booster immunization on day 28. Challenged
mice experienced a transient body weight loss for the first 4 days
post-challenge, but quickly regained their pre-challenge body
weights. One hundred percent of unvaccinated controls died
with an associated weight loss as observed earlier (Figure 9B).
Determination of bacterial burdens in all the surviving mice
on day 45 post-challenge resulted in recovery of no bacteria,
indicating generation of a sterilizing immunity in the vaccinated
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FIGURE 6 | Tetra-antigen TMV vaccine induces potent recall response in immunized mice. (A) C57BL/6 mice (n = 3–4) were immunized as shown. Mice were
sacrificed on day 84 post-primary immunization and single cell spleen suspensions were prepared. BMDMs isolated from syngeneic C57BL/6 mice were infected
either with F. tularensis LVS (B) or F. tularensis SchuS4 (C) at an MOI of 100 (100:1 bacteria:cell ratio), for 2 h followed by gentamicin treatment for 2 h. The infected
BMDMs were then overlaid with splenocytes isolated from immunized mice at 1:1 ratio. Splenocytes isolated from naïve mice (n = 3) were used as controls. The
culture supernatants from co-culture were analyzed for IFN-γ and IL-17 levels 24, 48, and 120 h later by CBA. The limits of detection for IL-17 and IFN-γ by CBA are
18.9 and 3.7 pg/ml, respectively. The results are representative of two independent experiments. The data were analyzed by one-way ANOVA followed by
Bonferroni’s correction and P-values were determined.
mice. In another experiment, C57BL/6 mice were immunized
on days 0 and 28 with a mixture of unconjugated recombinant
DnaK, OmpA, SucB, and Tul4 proteins (10 µg/each) along
with CpG adjuvant (20 µg) using the concentrations similar to
those present in the tetra-antigen TMV vaccine. The mice were
challenged i.n. with 1 × 105 CFU of F. tularensis LVS. It was
observed that only 50% mice survived the challenge indicating
that the protective efficacy declines if a mixture of unconjugated
proteins rather than TMV-conjugated proteins are used in a
vaccine formulation (data not shown). Collectively, these results
demonstrate that there is potential for further optimization of
an effective single dose immunization, or full protection with a
single booster immunization. These data demonstrate the greatly
improved protective efficacy of the tetra-antigen TMV vaccine
that includes TMV-SucB.
We also investigated the requirements for a protective
immune response in mice vaccinated with tetra-antigen TMV
vaccine. We immunized IFN-γ knockout (B6.IFN-γ−/−) mice
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FIGURE 7 | Tetra-antigen TMV vaccine induces long-lasting immunity against lethal F. tularensis LVS challenge. (A) C57BL/6 mice were immunized i.n. on days 0,
14, and 28 with tetra-antigen TMV vaccine. These mice received an additional booster with half the dose on day 91 post-primary immunization and were challenged
i.n. with 1 × 105 CFU (10LD100) of F. tularensis LVS on day 163 post-primary immunization. (B) Mice (n = 7/group) were observed for mortality and morbidity by
monitoring survival and body weights. The results shown are from a single experiment conducted. The data are represented as mean ± SD. The survival results are
expressed as Kaplan–Meier survival curves and the statistical analysis was performed by log-rank test.
with tetra-antigen TMV vaccine followed by a single booster
immunization on day 28 (Figure 9A). The immunized mice
were challenged i.n. with 10LD100 of F. tularensis LVS. It was
observed that vaccinated or unvaccinated B6.IFN-γ−/− mice
died in a similar fashion and much earlier (median survival
time, MST = 6) than the unvaccinated B6.IFN-γ+/+ control
mice (MST = 8) (Figure 9C). These results indicate that IFN-γ
is absolutely required for generation of a protective immune
response in mice immunized with tetra-antigen TMV vaccine.
The antibody responses in B6.IFN-γ+/+ and B6.IFN-γ−/−
mice immunized with tetra-antigen TMV vaccine on day 49
post-primary immunization were determined next. Analysis of
F. tularensis-specific total IgG, IgG1, IgG2b, and IgG2c isotypes
revealed no differences in antibody levels between immunized
B6.IFN-γ+/+ and B6.IFN-γ−/− mice (Table 3). Similarly, no
differences in antigen-specific antibody responses were observed
between immunized B6.IFN-γ+/+ and B6.IFN-γ−/− mice
(Figures 10A,B). These results demonstrate that the loss of
protection in immunized B6.IFN-γ−/− mice is not due to the
lack of antibody production. However, this may probably be due
to complete lack of a CMI response in immunized B6.IFN-γ−/−
mice.
DISCUSSION
Previous studies related to the development of tularemia
subunit vaccines have provided evidence that a single antigenic
component of F. tularensis is not sufficient for protection against
a lethal respiratory challenge (Conlan et al., 2002; Apicella
et al., 2010; Hickey et al., 2011; Kaur et al., 2012). On the
other hand, studies using more than one purified antigenic
components or a mixture of antigens either in the form of
outer membrane proteins or F. tularensis LVS and SchuS4
lysates have shown improved protection against respiratory
challenge with F. tularensis (Huntley et al., 2008; Ashtekar et al.,
2012; Richard et al., 2014, 2017). These studies indicate that a
complex mixture of antigens is needed in a vaccine formulation
for the induction of a protective immune response. However,
preparation of a complex mixture of antigens and their consistent
TABLE 2 | Antibody responses in mice immunized with tetra-antigen TMV vaccine.
Days post-primary immunization Total IgG# P-value∗ IgG1 P-value IgG2b P-value IgG2c P-value












163∧ 6.16 ± 0.43 5.01 ± 0.10 4.71 ± 0.16 5.94 ± 0.19
#Log10 titers expressed as mean ± SD (n = 3–4 mice/group). ˆMice received an additional half dose booster on day 91 post-primary immunization. ∗P-values were
determined by paired t-test. ns = not significant.
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FIGURE 8 | Single dose efficacy of the tetra-antigen TMV vaccine. (A) C57BL/6 mice were immunized i.n. on day 0 with tetra-antigen TMV vaccine and challenged
i.n. with 1 × 105 CFU (10LD100) of F. tularensis LVS on day 49 post-primary immunization. (B) Mice (n = 7/group) were observed for mortality and morbidity by
monitoring survival and body weights. The results are representative of two independent experiments conducted. The data are represented as mean ± SD. The
survival results are expressed as Kaplan–Meier survival curves and the statistical analysis was performed by log-rank test.
delivery may pose a potential problem when a vaccine has
to be manufactured on a large scale. In our previous study,
we reported a novel approach to uniformly deliver multiple
antigens of F. tularensis using TMV as a delivery platform.
Using two different approaches for preparation of a multi-antigen
TMV vaccine, we demonstrated that a cocktail of multiple
TMV–protein conjugates rather than all the proteins conjugated
to a single TMV virion is more effective in inducing a protective
immune response (Banik et al., 2015). This approach provided
a proof-of-concept for the efficacy of TMV as an efficient
carrier and a suitable platform for delivery of multiple antigenic
proteins of F. tularensis. There were several shortcomings in
the vaccine formulation that was used. Specifically, we observed
low protective efficacy of about 50% against a lethal respiratory
challenge dose of F. tularensis LVS and to achieve even this
level of protection, five immunizations by i.n. and s.c. routes
were needed. The reason behind this low protective efficacy was
that although the tri-antigen vaccine formulation consisting of
DnaK, OmpA, and Tul4 proteins of F. tularensis-induced potent
antigen-specific antibody responses, these were of TH2 type
predominated by IgG1 antibodies with very low levels of IgG2a,
IgG2b, and IgG2c isotype of antibodies were observed (Banik
et al., 2015). This study, however, provided us with an excellent
starting point for further vaccine improvement. In the current
study, we refined the TMV vaccine formulation and vaccination
strategy to reduce the number of immunizations, improve the
level of protection to 100% against a lethal respiratory challenge
with F. tularensis LVS, and to induce a potent and long-lasting
protective immune response in immunized mice.
There are several advantages of using TMV as a carrier
of multiple antigens of F. tularensis. Conjugation of antigens
to TMV increases particle size thereby improves its immune
uptake (Jennings and Bachmann, 2008; Manolova et al., 2008;
Oyewumi et al., 2010). TMV has distinct advantages over
nanoparticle and virus-like particle (VLP) formulations in that
it is a naturally occurring virus, is highly uniform in structure,
and can be easily produced at low cost. TMV provides a flexible
backbone for association of any subunit protein antigen of
interest from any source, and thus, can serve as a very versatile
carrier for a multitude of antigens. TMV is stable for decades
at room temperature, presenting the possibility that vaccine
formulations with TMV may not require refrigeration. TMV
is safe, as individuals world-wide are exposed to TMV in the
food chain, and/or through handling tobacco products (Liu
et al., 2013). Importantly, unlike other virus formulations, TMV
does not get neutralized specifically after repeated boosting;
either because of the limited immune reactivity of the TMV
coat proteins, or because of the masking effect resulting from
conjugation of proteins on its surface when used in a vaccine
formulation (Mallajosyula et al., 2014). From an immunological
stand point, the TMV architecture and size allow its rapid
uptake by antigen presenting cells and the positive sense
RNA core of TMV provides an additional adjuvant activity.
Previous studies from our group have shown that a single dose
immunization with TMV-hemagglutinin vaccine protects mice
against influenza challenge (Mallajosyula et al., 2014). Moreover,
a tri-antigen TMV vaccine protects 50% of the immunized
mice against respiratory tularemia caused by F. tularensis LVS
(Banik et al., 2015). Similarly, a recent study has demonstrated
the suitability of TMV as a delivery platform for a subunit
vaccine containing F1 and LcRV proteins of Yersinia pestis
that provided complete protection against pneumonic plague
in immunized mice (Arnaboldi et al., 2016). The goal of this
study was to develop a fully protective tularemia subunit vaccine
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FIGURE 9 | Protective efficacy after one booster immunization, and dependence on IFN-γ for the protection induced by the tetra-antigen TMV vaccine. (A) The
wild-type (B6.IFN-γ+/+) and IFN-γ knockout (B6.IFN-γ−/−) mice immunized i.n. on days 0 and 28 with the tetra-antigen TMV vaccine were challenged i.n. with
1 × 105 CFU (10LD100) of F. tularensis LVS on day 49 post-primary immunization. The B6.IFN-γ+/+ (B) and B6.IFN-γ−/− (C) mice (n = 7/group) were observed for
mortality and morbidity by monitoring survival and body weights. The data are represented as mean ± SD. The results are representative of two independent
experiments for B6.IFN-γ+/+ mice, and a single experiment for B6.IFN-γ−/− mice. The survival results are expressed as Kaplan–Meier survival curves and the
statistical analysis was performed by log-rank test.
using TMV as a delivery platform for multiple antigens of
F. tularensis.
We have developed a unique tetra-antigen vaccine
formulation by incorporating an additional SucB protein
into the tri-antigen formulation consisting of DnaK, OmpA, and
Tul4 proteins of F. tularensis. The inclusion of these antigens was
based on results from previous immunoproteomic studies and
analysis of antibodies against these proteins in human subjects
either infected naturally with Type A F. tularensis strains or
vaccinated with LVS. Two of the four antigens, DnaK and SucB
TABLE 3 | F. tularensis-specific antibody responses in B6.IFN-γ+/+ and B6.IFN-γ−/− mice immunized with tetra-antigen TMV vaccine on day 49 post-primary
immunization.
Mice Total IgG# P-value∗ IgG1 P-value IgG2b P-value IgG2c P-value












B6.IFN-γ−/− 6.27 ± 0.39 6.03 ± 0.42 5.14 ± 0.26 5.40 ± 0.24
#Log10 titers expressed as mean ± SD (n = 3–4 mice/group). ∞These values are same as shown in Table 1. ∗P-values were determined by paired t-test. ns = not
significant.
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FIGURE 10 | Total IgG antibody responses in wild-type and B6.IFN-γ−/− mice against each individual protein of tetra-antigen TMV vaccine. (A) The wild-type
(B6.IFN-γ+/+) and IFN-γ knockout (B6.IFN-γ−/−) mice were immunized i.n. on days 0 and 28 with the tetra-antigen TMV vaccine. (B) Antigen-specific total IgG
antibody titers in immunized B6.IFN-γ+/+ and B6.IFN-γ−/− mice against each individual protein of the tetra-antigen TMV vaccine were determined by ELISA on day
49 post-primary immunization. Pooled serum samples from immunized and the indicated control mice (n = 3 mice/group) were assayed in duplicate. The results are
expressed as absorbance at 450 nm (mean ± standard deviation). The cut-off absorbance values used to determine the end-point titers are indicated by dashed
lines and the actual values are shown in the box (top panels). The end-point titers are represented as Log10 values (bottom panel).
have almost exclusively been found to be reactive to serum from
humans, non-human primates, mice, and rabbits immunized
with F. tularensis LVS or from human patients who recovered
from a known infection with F. tularensis SchuS4 (Havlasova
et al., 2002, 2005; Eyles et al., 2007; Janovska et al., 2007). On
the other hand, Tul4 has been shown to stimulate toll-like
receptor 2 (TLR2) and elicit strong humoral as well as T-cell-
mediated responses (Sjostedt et al., 1990, 1992; Valentino et al.,
2009). Purified Tul4 from F. tularensis LVS incorporated into
immunostimulating complexes when used as a vaccine reduced
the hepatic and splenic colonization of F. tularensis, however,
failed to induce any protection in immunized mice (Golovliov
et al., 1995). An enhanced protective immune response was
observed in immunized mice when recombinant Tul4 was
used in combination with DnaK along with the GPI-0100
adjuvant (Ashtekar et al., 2012). Additionally, a combination
of recombinant Tul4/FopA proteins when used as a vaccine
prolonged the survival of immunized humanized mice following
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a challenge with F. tularensis LVS (Oh et al., 2017). The
OmpA-like protein was also identified in immunoproteomic
analysis (Huntley et al., 2007, 2008). Our previous studies have
described the role of OmpA protein in immunopathogenesis
and suppression of innate immune responses caused by
F. tularensis (Mahawar et al., 2012; Dotson et al., 2013). These
proteins were conjugated individually to the surface of TMV
and then each protein–TMV conjugate was blended in equal
concentrations to formulate a tetra-antigen TMV vaccine. As
reported earlier (Eyles et al., 2007; Oh et al., 2016) to divert the
IgG1-predominated TH2 response against the tri-antigen TMV
vaccine, we included a CpG adjuvant; a TLR9 agonist and a
potent inducer of TH1 type immune response in our vaccine
formulation.
A successful conjugation of DnaK, OmpA, SucB, and Tul4
protein to TMV was observed by the disappearance of free
protein and/or formation of high molecular weight complexes.
The manner in which the subunit proteins conjugate with TMV
depends on their molecular weights (Mallajosyula et al., 2014).
The larger the subunit protein, the fewer molecules of subunit
protein will associate with individual coat protein of the TMV
(17 kD in size) due to steric hindrance at the virus surface
(Figure 1A). This was specifically seen with DnaK protein and
thus higher levels of free TMV coat proteins were observed
at the end of conjugation reaction. On the other hand, other
proteins may associate with TMV coat protein on the surface
with least steric hindrance. Consequently, less amounts of free
TMV coat proteins as indicated by less intense staining on the
gels were observed at the end of successful conjugation with
OmpA, SucB, and Tul4 proteins. The successful conjugation
of these latter proteins to TMV resulted in formation of high
molecular weight complexes that were too big to pass through
the wells and thus were not seen on the gel (Figure 1B). In
each of these conjugation reactions, we observed the presence of
free TMV coat proteins depending on the conjugation efficacy
of the protein with the TMV. We have observed that 100% of
the control mice that receive TMV in equal concentration as
the mice receiving TMV-conjugate vaccine succumb to infection
following challenge with F. tularensis LVS (Banik et al., 2015).
These observations indicate that the presence of free TMV in the
tetra-antigen vaccine formulation may not contribute to any level
of protection against the F. tularensis LVS challenge. On the other
hand, the residual unconjugated proteins that may remain in our
vaccine formulation may contribute to protection in parallel with
the TMV-conjugated proteins. We observed that 50% of mice
immunized on days 0 and 28 with a mixture of unconjugated
recombinant DnaK, OmpA, SucB, and Tul4 proteins (10 µg
each) along with the CpG (20 µg) adjuvant survived the lethal
challenge with F. tularensis LVS (data not shown); while a similar
vaccination regimen with TMV-conjugated proteins resulted in
80% survival (Figure 9B). However, it is worth noting that
the concentrations of residual unconjugated proteins in our
tetra-antigen TMV vaccine formulation are expected to be
much lower than the mixture of unconjugated recombinant
proteins used for immunization, and thus are not expected to
contribute in a significant way to the protection observed in
mice immunized with the tetra-antigen TMV vaccine. Previous
studies using an identical approach for conjugation of antigenic
proteins of influenza virus and Y. pestis to TMV have recorded
100% protection in mice against challenges with H1N1 influenza
virus and CO92pgm strain of Y. pestis, respectively. However,
the protection levels against influenza and Y. pestis were
reduced to 20% and 50%, respectively, when unconjugated rather
than TMV-conjugated proteins were used for immunizations
(Arnaboldi et al., 2016). Collectively, these and the results from
our studies demonstrate that conjugation of antigens to TMV
enhances the protective immune response than those observed
for a mixture of unconjugated proteins administered with or
without adjuvants.
We demonstrate that immunizing mice with two booster
immunizations on days 14 and 28 of the primary i.n.
immunization with refined tetra-antigen TMV vaccine
formulation provides 100% against a respiratory challenge with
10LD100 of F. tularensis LVS. Any alteration in this immunization
regimen either by giving none or just one booster immunization
reduces the protective efficacy of the vaccine. These results
strongly suggest that the composition of the tetra-antigen
vaccine that includes SucB has significantly improved protective
efficacy even after just one dose. This is in contrast with previous
observations that a prime-boost immunization strategy was
absolutely required for achieving protection in mice immunized
with subunit vaccines of F. tularensis (Jia et al., 2013; Richard
et al., 2017; Roberts et al., 2017). The effectiveness of the tetra-
antigen vaccine is evidenced by a sterilizing immunity, minimal
pathology, potent antibody-mediated responses associated with
a long-lasting recall, and prolonged duration of immunity. In
contrast to the IgG1-predominated response observed in mice
immunized with the tri-antigen vaccine without an adjuvant,
the tetra-antigen vaccine induced mixed TH1 and TH2 biased
antibody responses with higher levels of IgG2b and IgG2c
antibodies. It has been reported that a mixed TH1 and TH2
response is required for protection against F. tularensis infection
(Bitsaktsis et al., 2009). The inclusion of CpG adjuvant, which
is a known TLR9 agonist with the capacity to activate innate
immune cells, may have resulted in a switch toward a TH1
biased immunity associated with an increase in IgG2b and IgG2c
levels.
Induction of a select group of cytokines such as IFN-γ and
IL-17 in an ex vivo assay with splenocytes from immunized
mice has been reported to be an indicator of protective efficacy
and ability of the vaccine to induce a memory recall response
(Paranavitana et al., 2010; De Pascalis et al., 2012; Mahawar
et al., 2013). The recall responses were evaluated on day
84 post-primary immunization. Similar recall responses were
observed in ex vivo assays irrespective of whether these were
conducted using F. tularensis LVS or F. tularensis SchuS4-infected
BMDMs. Induction of IFN-γ upon recall stimulation is a
hallmark of memory response against F. tularensis. Moreover, a
similar recall response against SchuS4 as that observed against
F. tularensis LVS suggests that the tetra-antigen vaccine may
also be protective against a F. tularensis SchuS4 challenge
in mice. Levels of IFN-γ and IL-17 have been shown to be
associated with protection against F. tularensis SchuS4 challenge
in vaccinated mice. It has also been reported that these cytokines
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are induced immediately following challenge with F. tularensis
SchuS4 (Lin et al., 2009; Khader and Gopal, 2010). Further,
the IL-17-dependent induction of IFN-γ is required for the
control of F. tularensis infection (Paranavitana et al., 2010).
Collectively, our ex vivo assays demonstrate the ability of the
tetra-antigen TMV vaccine to induce a strong memory recall
response. The ability of the tetra-antigen TMV vaccine is also
evidenced by the fact that boosting of immunized mice with
half the dose of vaccine on day 91 post-primary immunization
enhanced the antibody response on day 163 compared to
that observed for day 84 post-primary immunization. This
enhanced immune response also resulted in 80% protection
in immunized mice when challenged on day 163 post-primary
immunization. These studies convincingly demonstrate the
long-term protection induced by the tetra-antigen TMV
vaccine.
Interferon-gamma plays an important role in clearance of
Francisella infection (Polsinelli et al., 1994). IFN-γ stimulates
alveolar macrophages and recruits other phagocytic cells
especially neutrophils to exert its protective effect in response
to Francisella infection (Steiner et al., 2017). It has been shown
that IFN-γ is required for protection during both the primary
and secondary respiratory infection caused by F. tularensis
and neutralization of IFN-γ in vaccinated mice results in a
drastic weight loss and increased bacterial burden (Roberts
et al., 2014). IFN-γ has also been shown to be important
during the priming and effector phase of F. tularensis infection
(Elkins et al., 2010). Moreover, passive transfer of antibodies
into naïve IFN-γ−/− mice fails to provide any protection
against subsequent challenge with F. tularensis (Rhinehart-Jones
et al., 1994; Kirimanjeswara et al., 2007). Our results show that
vaccination of B6.IFN-γ−/− mice fails to induce any degree
of protection against a lethal i.n. challenge. The immunized
B6.IFN-γ−/− mice died similarly to unvaccinated B6.IFN-γ−/−
control mice. However, the B6.IFN-γ−/− mice had similar levels
of antibodies as observed in the wild-type B6.IFN-γ+/+ mice
which were protected. These results indicate that loss of IFN-γ
does not impair generation of antibody-mediated response but
may affect the generation of T-CMI responses. However, adoptive
transfer of T-cells from immunized wild-type mice or passive
transfer of hyperimmune serum (Kirimanjeswara et al., 2007)
to naïve IFN-γ−/− mice fails to provide protection against
subsequent i.n. or i.p. challenge with F. tularensis. Collectively,
these results suggest that the B6.IFN-γ−/− mice are not defective
in the generation of F. tularensis-specific antibody responses.
However, they completely lack cell-mediated responses. In the
absence of T-cell help, antibodies alone fail to clear infection
in IFN-γ−/− mice immunized with tetra-antigen TMV. Based
on these observations, it can be speculated that both primed T
cells as well as F. tularensis-specific antibodies may be required
for protection in IFN-γ−/− mice. Nevertheless, results from the
present study highlight the importance of IFN-γ in generation of
a protective immune response.
We demonstrate that the tetra-antigen vaccine consisting
of DnaK, OmpA, SucB, and Tul4 conjugated to TMV and
admixed with CpG exhibits a better protective efficacy than
DanK, OmpA, and Tul4 tri-antigen vaccine without any
adjuvant (Banik et al., 2015). The better protective efficacy of
this vaccine could result from a number of factors. Firstly,
we observed that the humoral immune response generated
following tetra-antigen vaccine with CpG was a mix of
TH1 and TH2 type rather than a IgG1-predominated TH2
type response observed with the tri-antigen vaccine (Banik
et al., 2015). This observation is supported by elevated
pre-challenge levels of F. tularensis LVS-specific total IgG, IgG1,
IgG2b, and IgG2c antibodies in tetra-antigen vaccinated mice.
Secondly, potent SucB-specific antibody responses similar to
those observed for DnaK and Tul4 were also generated in
mice vaccinated with tetra-antigen vaccine. Additionally, CpG
adjuvant induces a rapid and significant humoral immune
response (Ciabattini et al., 2016), attenuation of TH2 type
response, and induction of TH1 phenotype associated with
IFN-γ or IL-17 dominated lung inflammation (Mirotti et al.,
2017). We speculate that elevated levels of IgG2b and IgG2c
antibodies may have resulted from inclusion of CpG adjuvant
in our vaccine formulation. A combination of Tul4 and the
outer membrane protein FopA along with the CpG adjuvant
has been reported to enhance in vitro and in vivo immune
responses compared to those observed for proteins alone,
demonstrating the immune-potentiating action of the CpG
adjuvant in the context of F. tularensis antigens (Oh et al.,
2016). Our additional studies have shown that splenocytes
from vaccinated mice induced similar ex vivo recall response
following stimulation with DnaK, SucB, and Tul4 and these
responses were of higher magnitude that those observed
for splenocytes stimulated with OmpA protein (data not
shown). These results indicate that addition of SucB to the
vaccine formulation enhances the level of protection to 100%.
However, SucB may not be the sole determinant of enhanced
protective efficacy of the tetra-antigen TMV vaccine as other
antigens of the vaccine formulation and the CpG adjuvant
also contributes to the generation of a protective immune
response.
To conclude, this study represents a very important milestone
in the development of a multi-antigen subunit vaccine for
prevention of tularemia. This study provides a proof-of-concept
that a fully protective vaccine can be developed by incorporating
the right formulation of protective antigens, using TMV as an
i.n. delivery platform. Although this vaccine was not tested for
its protective efficacy against the virulent F. tularensis SchuS4
strain, the recall response studies using F. tularensis SchuS4
provides support for the hypothesis that this vaccine may be
effective against respiratory tularemia caused by F. tularensis
SchuS4 as well. Furthermore, the results presented establish a
foundation for the development of an effective vaccine against
F. tularensis SchuS4 if the current formulation is only partially
protective. Using TMV platform with a flexible plug-n-play
approach allows for incorporation of additional F. tularensis
antigens until a vaccine formulation than can provide complete
protection against the fatal tularemia caused by F. tularensis
SchuS4 is developed. Our future efforts are directed at developing
a fully protective vaccine against F. tularensis SchuS4 using TMV-
based delivery of multiple antigens of F. tularensis as described in
this manuscript.
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